Deutsche Bank provided a list of the major companies in the benchmark S&P 500 index that are not based in the United States. We cross-referenced the list with the Merrill Lynch research…
24/7 Wall St. covers many of each morning’s key analyst upgrades and downgrades. After a second look, it turns out that some key analyst calls are driving some of the more active…
Thursday's top analyst upgrades, downgrades and initiations include Bankrate, Eli Lilly, Embraer, Oracle and Southwest Airlines.
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is trying to transform itself by making its generics business even larger if it can pull off its desire to acquire Mylan N.V. (NASDAQ: MYL). The…
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
Back in November of 2010, 24/7 Wall St. first issued a list of stocks to own for the next decade. Even long-term investors need to assess their portfolios from time to time.
If there was ever a time for investors to be concerned about valuations, it might be now. With the market trading at over 18 times earnings, things are getting a little pricey.
Teva Pharmaceutical Industries has just approached Mylan with a public takeover bid valued at $82 per share in cash and stock.
Independent research firm Argus has weighed in on Mylan and Perrigo prior to the acquisition.
Friday's top analyst upgrades, downgrades and initiations include Apple, Citrix Systems, Kythera Biopharmaceuticals, Mylan, Netflix and Weatherford International.
Generic drug maker Mylan has proposed to acquire rival Perrigo for $205 per share in cash and stock.
Mylan has announced that it will have a 35 million share secondary offering. At Tuesday's closing price of $59.35, the offering would be valued at $2.08 billion.
A new research report from the technical team at RBC cites Bristol-Myers Squibb, Eli Lilly, Mylan and Perrigo as stocks that may continue to show sector leadership.
ThinkstockMonday after the markets closed, Mylan, Inc. (NASDAQ: MYL) reported its fourth-quarter financial results as in line with estimates. Specifically the company had $1.05 in earnings per share (EPS) and $2.08 billion…
Chris Lange What are investors, and patients, supposed to think when is launching a generic version of Diovan?
